Novo Nordisk A/S (NVO)
Novo Nordisk A/S (NVO) carries a ŷRobot AI score of 57 out of 100. The model's fair value estimate is $39.90, 4.6% above the last close of $38.16. The chart signal reads Hold.
| Metric | NVO |
|---|---|
| AI score | 57 / 100 |
| Chart signal | Hold |
| Fair value estimate | $39.90 |
| Upside to fair value | 4.6% |
| Previous close | $38.16 |
| P/E | 9.60 |
| Price / sales | 2.43 |
| Market cap | $165.67B |
| EPS | 3.99 |
| Revenue growth | 19.0% |
| 1-year price change | -2.0% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about NVO
Is NVO overvalued or undervalued right now?
As of Oct 8, 2026, ŷRobot's fair-value model estimates Novo Nordisk A/S (NVO) at $39.90 against a last close of $38.16, implying 4.6% upside to the model's estimate.
Is NVO's chart signal bullish or bearish?
The chart-signal model classifies NVO as Neutral as of Oct 8, 2026, with a signal score of 0.11 on a -1 to 1 scale.
What is NVO's ŷRobot AI score?
NVO scores 57 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 8, 2026.
Is NVO stock expensive on P/E and P/S?
NVO trades at 9.6 times earnings and 2.4 times sales as of Oct 8, 2026.
What does NVO's seasonal forecast show?
ŷRobot's seasonal forecast curve for NVO reads +0.2% at 30 days, +1.6% at 90 days, and -2.0% at one year as of Oct 8, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is NVO growing?
Novo Nordisk A/S's revenue growth is +19.0% and free-cash-flow growth is +1.1% on the latest reported figures.
NVO chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.